Welcome to our dedicated page for AN2 Therapeutics SEC filings (Ticker: ANTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AN2 Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company developing small-molecule therapeutics from a boron chemistry platform. Its disclosures cover common stock registration, operating and financial results, clinical and regulatory updates, risk factors and material events related to its development pipeline.
ANTX filings also include proxy materials for director elections and auditor ratification, 8-K reports on material agreements, equity and warrant financing arrangements, at-the-market sale agreements, equity incentive plan matters, option repricing, officer appointments, governance changes and capital-structure disclosures.
AN2 Therapeutics reported a 2025 net loss of $35.2M, improved from $51.3M in 2024, as it narrowed research and administrative spending. Fourth-quarter net loss was $8.7M, or $0.29 per share.
Full-year R&D expenses fell to $24.8M from $40.5M, while G&A declined to $13.3M from $14.1M. There were no restructuring charges in 2025, compared with $2.2M a year earlier.
The company ended 2025 with $60.0M in cash, cash equivalents and investments and entered a March 2026 private placement for roughly $40M in gross proceeds. Management projects this funding will support operations into 2029 while advancing Phase 2 programs in polycythemia vera, M. abscessus lung disease and Chagas disease, plus two oncology candidates.
AN2 Therapeutics, Inc. disclosure: Commodore Capital LP, Commodore Capital Master LP and related parties report beneficial ownership of 3,697,435 shares of Common Stock as of March 9, 2026. The total comprises 2,333,713 shares held and 1,363,722 shares issuable upon exercise of a Pre-Funded Warrant. The Pre-Funded Warrant is subject to a 9.99% Beneficial Ownership Limitation. Ownership percentages are calculated using 37,011,357 shares outstanding, derived from the issuer's reported counts as of November 3, 2025 and a private placement closed on or about March 10, 2026.
AN2 Therapeutics, Inc. (ANTX) owners filed a Schedule 13G reporting shared beneficial ownership stakes in Common Stock by a group led by Millennium affiliates and Integrated Core Strategies. The filing lists holdings of 2,237,102 shares (6.3%) for Millennium Management LLC and affiliates and 2,135,044 shares (6.0%) for Integrated Core Strategies (US) LLC.
The percent figures are calculated using 35,647,635 shares outstanding, which the filing ties to the issuer's reported 27,402,024 shares outstanding as of November 3, 2025 plus 8,245,611 shares issued in a private placement closed on or about March 10, 2026. The filing is a joint Schedule 13G with a Joint Filing Agreement dated March 12, 2026.
AN2 Therapeutics reports beneficial ownership by Vivo Opportunity entities. Vivo Opportunity Fund Holdings, L.P. holds 2,864,346 shares of Common Stock (representing 8.0%) and Vivo Opportunity Cayman Fund, L.P. holds 289,294 shares (0.8%), as disclosed in a joint Schedule 13G filing.
The percent calculations are based on 35,647,635 shares outstanding, comprising 27,402,024 shares outstanding as of November 3, 2025 and 8,245,611 shares issued at the closing of a private placement on March 10, 2026.
AN2 Therapeutics, Inc. entered into a securities purchase agreement for a private placement expected to raise approximately $40 million in gross proceeds. The company is selling 8,245,611 shares of common stock at $2.85 per share and pre-funded warrants to purchase up to 5,789,493 shares at $2.84999 per warrant.
Each pre-funded warrant carries a nominal exercise price of $0.00001 per share, is exercisable immediately and remains outstanding until fully exercised, subject to a beneficial ownership cap starting at 9.99%, adjustable up to 19.99% after 61 days upon notice. The private placement is expected to close on March 10, 2026, with customary conditions.
AN2 agreed to file a resale registration statement covering the new shares and warrant shares within 30 days after closing and to use reasonable best efforts to have it declared effective within agreed timeframes. The company also agreed to temporary restrictions on issuing additional equity or equivalents until the registration is effective or 60 days after closing, whichever comes first.
AN2 Therapeutics principal accounting officer Sarah Joanne Williams sold 327 shares of common stock at $1.06 per share. The March 3, 2026 open‑market sale was made under grant terms to satisfy tax withholding from Restricted Stock Units vesting on February 28, 2026. After this transaction she directly holds 66,848 shares, and her holdings include multiple RSU awards that vest in installments through future years, subject to her continued service.
Eizen Joshua M reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics officer Joshua M. Eizen reported new equity awards. He was granted a stock option covering 100,000 shares, which vests in equal monthly installments over four years from January 1, 2026, subject to continued service. He also received 50,000 restricted stock units that vest 25% annually over four years from January 1, 2026, on the same service condition. Following these awards, he directly owns 207,499 shares of common stock, which includes prior RSU grants and a 5,000-share purchase under the 2022 Employee Stock Purchase Plan on March 31, 2025.
Day Lucy reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics, Inc. Chief Financial Officer Lucy Day reported equity awards consisting of a stock option for 77,000 shares and a grant of 38,000 shares of common stock on February 20, 2026. The common stock amount represents restricted stock units that vest 1/4 annually over four years from January 1, 2026, subject to continued service. The option vests 1/48 monthly over four years from the same date on a continued-service basis. Her common stock holdings total 118,363 shares, reflecting prior RSU grants of 27,500 and 46,500 units with annual vesting from January 1, 2024 and January 1, 2025, and a 5,000-share purchase under the 2022 Employee Stock Purchase Plan on March 31, 2025.
Williams Sarah Joanne reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics Principal Accounting Officer Sarah Joanne Williams received a grant of 48,375 shares of common stock in the form of restricted stock units. The RSUs vest over four years, with one quarter of the shares vesting annually from January 1, 2026, contingent on her continued service.
After this award, Williams directly holds 67,175 shares, including prior RSU grants described in the footnotes. Those earlier RSUs vest on separate annual and quarterly schedules, also conditioned on her remaining in service with the company.
AN2 Therapeutics, Inc. director and Chief Executive Officer Eric Easom reported new equity awards. He received a stock option for 224,500 shares at an exercise price of $0.0000 per share and a grant of 112,250 shares of Common Stock on February 20, 2026.
The 112,250-share grant represents restricted stock units that vest in 25% increments annually over four years from January 1, 2026, subject to continuous service. The option vests 1/48 of the shares monthly over four years from January 1, 2026. Easom also reports indirect ownership of Common Stock through the Easom Living Trust and two irrevocable trusts.